Behavioral effects of quinupramine, a new tricyclic antidepressant

Showa Ueki, Tsuneyuki Yamamoto, Takao Shimazoe, Shigenobu Shibata, Yoshihiro Tani, Koichi Machida, Masakazu Hojo, Yoichi Yoshida, Hiroshi Tatsumi

Research output: Contribution to journalArticle

Abstract

The effects of a new tricyclic antidepressant quinupramine (5-(3-quinuclidinyl)-10,11 dihydro-5H-dibenz 〔b, f〕 azepine) on various animal behaviors were examined in mice and rats and compared with those of imipramine, amitriptyline and maprotiline. Quinupramine antagonized haloperidol-induced catalepsy and tetrabenazine-induced ptosis and potentiated methamphetamine- and apomorphine-induced stereotyped behavior. These effects were almost the same as or even more potent than those of imipramine and amitriptyline. Quinupramine decreased locomotor activity in mice, but potentiated methamphetamine induced hyperactivity to a greater degree than imipramine and amitriptyline. On the other hand, quinupramine inhibited muricide in accumbens-lesioned rats, but did not prominently inhibit muricide in olfactory-bulbectomized and raphe-lesioned rats. Quinupramine decreased the duration of immobility in low doses without affecting locomotor activity, and this effect was almost the same as that of imipramine and amitriptyline and more potent than that of maprotiline. Quinupramine antagonized physostigmine lethality and oxotremorine-induced tremor, suggesting that quinupramine has a central anticholinergic action. Quinupramine, like imipramine and amitriptyline, has no effect on conditioned avoidance behavior. In conclusion, quinupramine generally has the same behavioral profile as typical tricyclic antidepressants, but it has somewhat different effects from imipramine and amitriptyline since quinupramine has a potent central anticholinergic and a weak antimuricide effect.

Original languageEnglish
Pages (from-to)359-369
Number of pages11
JournalFolia Pharmacologica Japonica
Volume91
Issue number6
DOIs
Publication statusPublished - Jan 1 1988

Fingerprint

Tricyclic Antidepressive Agents
Amitriptyline
Imipramine
Maprotiline
Methamphetamine
Cholinergic Antagonists
Locomotion
Tetrabenazine
quinupramine
Avoidance Learning
Oxotremorine
Stereotyped Behavior
Catalepsy
Animal Behavior
Physostigmine
Apomorphine
Tremor
Haloperidol

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Ueki, S., Yamamoto, T., Shimazoe, T., Shibata, S., Tani, Y., Machida, K., ... Tatsumi, H. (1988). Behavioral effects of quinupramine, a new tricyclic antidepressant. Folia Pharmacologica Japonica, 91(6), 359-369. https://doi.org/10.1254/fpj.91.359

Behavioral effects of quinupramine, a new tricyclic antidepressant. / Ueki, Showa; Yamamoto, Tsuneyuki; Shimazoe, Takao; Shibata, Shigenobu; Tani, Yoshihiro; Machida, Koichi; Hojo, Masakazu; Yoshida, Yoichi; Tatsumi, Hiroshi.

In: Folia Pharmacologica Japonica, Vol. 91, No. 6, 01.01.1988, p. 359-369.

Research output: Contribution to journalArticle

Ueki, S, Yamamoto, T, Shimazoe, T, Shibata, S, Tani, Y, Machida, K, Hojo, M, Yoshida, Y & Tatsumi, H 1988, 'Behavioral effects of quinupramine, a new tricyclic antidepressant', Folia Pharmacologica Japonica, vol. 91, no. 6, pp. 359-369. https://doi.org/10.1254/fpj.91.359
Ueki, Showa ; Yamamoto, Tsuneyuki ; Shimazoe, Takao ; Shibata, Shigenobu ; Tani, Yoshihiro ; Machida, Koichi ; Hojo, Masakazu ; Yoshida, Yoichi ; Tatsumi, Hiroshi. / Behavioral effects of quinupramine, a new tricyclic antidepressant. In: Folia Pharmacologica Japonica. 1988 ; Vol. 91, No. 6. pp. 359-369.
@article{4673105ab251475c923a6ebb5750ed40,
title = "Behavioral effects of quinupramine, a new tricyclic antidepressant",
abstract = "The effects of a new tricyclic antidepressant quinupramine (5-(3-quinuclidinyl)-10,11 dihydro-5H-dibenz 〔b, f〕 azepine) on various animal behaviors were examined in mice and rats and compared with those of imipramine, amitriptyline and maprotiline. Quinupramine antagonized haloperidol-induced catalepsy and tetrabenazine-induced ptosis and potentiated methamphetamine- and apomorphine-induced stereotyped behavior. These effects were almost the same as or even more potent than those of imipramine and amitriptyline. Quinupramine decreased locomotor activity in mice, but potentiated methamphetamine induced hyperactivity to a greater degree than imipramine and amitriptyline. On the other hand, quinupramine inhibited muricide in accumbens-lesioned rats, but did not prominently inhibit muricide in olfactory-bulbectomized and raphe-lesioned rats. Quinupramine decreased the duration of immobility in low doses without affecting locomotor activity, and this effect was almost the same as that of imipramine and amitriptyline and more potent than that of maprotiline. Quinupramine antagonized physostigmine lethality and oxotremorine-induced tremor, suggesting that quinupramine has a central anticholinergic action. Quinupramine, like imipramine and amitriptyline, has no effect on conditioned avoidance behavior. In conclusion, quinupramine generally has the same behavioral profile as typical tricyclic antidepressants, but it has somewhat different effects from imipramine and amitriptyline since quinupramine has a potent central anticholinergic and a weak antimuricide effect.",
author = "Showa Ueki and Tsuneyuki Yamamoto and Takao Shimazoe and Shigenobu Shibata and Yoshihiro Tani and Koichi Machida and Masakazu Hojo and Yoichi Yoshida and Hiroshi Tatsumi",
year = "1988",
month = "1",
day = "1",
doi = "10.1254/fpj.91.359",
language = "English",
volume = "91",
pages = "359--369",
journal = "Folia Pharmacologica Japonica",
issn = "0015-5691",
publisher = "Japanese Pharmacological Society",
number = "6",

}

TY - JOUR

T1 - Behavioral effects of quinupramine, a new tricyclic antidepressant

AU - Ueki, Showa

AU - Yamamoto, Tsuneyuki

AU - Shimazoe, Takao

AU - Shibata, Shigenobu

AU - Tani, Yoshihiro

AU - Machida, Koichi

AU - Hojo, Masakazu

AU - Yoshida, Yoichi

AU - Tatsumi, Hiroshi

PY - 1988/1/1

Y1 - 1988/1/1

N2 - The effects of a new tricyclic antidepressant quinupramine (5-(3-quinuclidinyl)-10,11 dihydro-5H-dibenz 〔b, f〕 azepine) on various animal behaviors were examined in mice and rats and compared with those of imipramine, amitriptyline and maprotiline. Quinupramine antagonized haloperidol-induced catalepsy and tetrabenazine-induced ptosis and potentiated methamphetamine- and apomorphine-induced stereotyped behavior. These effects were almost the same as or even more potent than those of imipramine and amitriptyline. Quinupramine decreased locomotor activity in mice, but potentiated methamphetamine induced hyperactivity to a greater degree than imipramine and amitriptyline. On the other hand, quinupramine inhibited muricide in accumbens-lesioned rats, but did not prominently inhibit muricide in olfactory-bulbectomized and raphe-lesioned rats. Quinupramine decreased the duration of immobility in low doses without affecting locomotor activity, and this effect was almost the same as that of imipramine and amitriptyline and more potent than that of maprotiline. Quinupramine antagonized physostigmine lethality and oxotremorine-induced tremor, suggesting that quinupramine has a central anticholinergic action. Quinupramine, like imipramine and amitriptyline, has no effect on conditioned avoidance behavior. In conclusion, quinupramine generally has the same behavioral profile as typical tricyclic antidepressants, but it has somewhat different effects from imipramine and amitriptyline since quinupramine has a potent central anticholinergic and a weak antimuricide effect.

AB - The effects of a new tricyclic antidepressant quinupramine (5-(3-quinuclidinyl)-10,11 dihydro-5H-dibenz 〔b, f〕 azepine) on various animal behaviors were examined in mice and rats and compared with those of imipramine, amitriptyline and maprotiline. Quinupramine antagonized haloperidol-induced catalepsy and tetrabenazine-induced ptosis and potentiated methamphetamine- and apomorphine-induced stereotyped behavior. These effects were almost the same as or even more potent than those of imipramine and amitriptyline. Quinupramine decreased locomotor activity in mice, but potentiated methamphetamine induced hyperactivity to a greater degree than imipramine and amitriptyline. On the other hand, quinupramine inhibited muricide in accumbens-lesioned rats, but did not prominently inhibit muricide in olfactory-bulbectomized and raphe-lesioned rats. Quinupramine decreased the duration of immobility in low doses without affecting locomotor activity, and this effect was almost the same as that of imipramine and amitriptyline and more potent than that of maprotiline. Quinupramine antagonized physostigmine lethality and oxotremorine-induced tremor, suggesting that quinupramine has a central anticholinergic action. Quinupramine, like imipramine and amitriptyline, has no effect on conditioned avoidance behavior. In conclusion, quinupramine generally has the same behavioral profile as typical tricyclic antidepressants, but it has somewhat different effects from imipramine and amitriptyline since quinupramine has a potent central anticholinergic and a weak antimuricide effect.

UR - http://www.scopus.com/inward/record.url?scp=0023941894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023941894&partnerID=8YFLogxK

U2 - 10.1254/fpj.91.359

DO - 10.1254/fpj.91.359

M3 - Article

C2 - 3417209

AN - SCOPUS:0023941894

VL - 91

SP - 359

EP - 369

JO - Folia Pharmacologica Japonica

JF - Folia Pharmacologica Japonica

SN - 0015-5691

IS - 6

ER -